Business Context and Reporting Period
Envoy Medical, Inc. (Nasdaq: COCH), a Delaware corporation, filed this Form 8-K on February 11, 2026, to report the commencement and subsequent closing of a best efforts public offering. The company is an emerging growth company focused on developing the Acclaim CI device, currently undergoing FDA pivotal clinical studies.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $30.0 million from the initial sale of securities.
- Potential Additional Proceeds: Up to approximately $48.0 million if all warrants are fully exercised for cash (not guaranteed).
- Offering Price: $0.40 per share (or $0.3999 per Pre-Funded Warrant) including accompanying warrants.
- Placement Agent Fees: 7% of aggregate gross proceeds paid to H.C. Wainwright & Co., LLC.
- Use of Proceeds: Working capital and general corporate purposes to fund operations during the FDA pivotal clinical study for the Acclaim CI device.
Material Changes and Transaction Structure
The company executed a complex capital raise involving the sale of:
- 47,946,150 shares of Class A Common Stock.
- 27,053,850 Pre-Funded Warrants (exercisable at $0.0001 per share).
- 45,000,000 Series A-1 Warrants (exercise price $0.40; expire 2 years post-exercise or 30 days after Milestone 1).
- 75,000,000 Series A-2 Warrants (exercise price $0.40; expire 5 years post-exercise or 30 days after Milestone 2).
Insider Participation: Company insiders, including directors and officers, purchased approximately 2,250,000 shares for roughly $0.9 million. A beneficial owner of 35.6% of outstanding shares purchased 18,750,000 shares for $7.5 million. All insiders paid the same price as other investors.
Guidance, Milestones, and Risks
Warrant Milestones: The expiration of the Series A-1 and A-2 warrants is tied to specific regulatory milestones:
- Milestone 1: Public announcement of the submission of a Premarket Approval (PMA) Application to the FDA for the Acclaim CI device.
- Milestone 2: Public announcement of FDA marketing approval for the Acclaim CI device.
Stockholder Approval: The Company must seek stockholder approval for the issuance of shares upon exercise of Common Warrants within 90 days of the offering. If not obtained at the first meeting, the Company must call a meeting every 90 days thereafter until approval is granted or warrants expire.
Lock-Up Provisions: The Company agreed not to issue new equity or file registration statements for 60 days post-closing, and is restricted from variable rate transactions for one year.
Risks: There is no guarantee that warrants will be exercised. The filing notes that representations in the purchase agreement are for risk allocation between parties and may not reflect materiality standards for general stockholders.
Key Facts for Investor Verification
- Verify the exact net proceeds after deducting the 7% placement fee and other offering expenses.
- Confirm the timeline for the stockholder meeting required to approve warrant exercises (must occur within 90 days of February 12, 2026).
- Monitor the status of the Acclaim CI device's FDA PMA submission (Milestone 1) and approval (Milestone 2) as these trigger warrant expirations.
- Review the dilution impact of the 122,000,000 total warrants issued (Series A-1, A-2, and Pre-Funded) if exercised.
- Check the company's cash runway relative to the $30 million raised to ensure sufficiency for the pivotal clinical study.